TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05487417
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Minocycline is a tetracycline antibiotic. Previous studies have confirmed that its application in stroke patients has good efficacy and safety, suggesting that it could become a synergistic treatment of mechanical thrombectomy.
Study: NCT04393103
Drug: Intralipid, 20% Intravenous Emulsion
Normalized name: Intralipid, 20% intravenous emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine will be administered to ALL PATIENTS by doubling dose method which comprised of administering atropine start-ing from 2mg and to double the dose and administer till com-plete atropinization. Following this an infusion of 10-20% of the atropinizing dose was given every hour.~* Group A (Control Group) : Follow Up of 30 patients.~* Group B (Study Group): 30 patients will receive intralipid AS AN ADJUVANT Three boluses of IFE 15 mg/kg were given over 3 minutes, 20 minutes apart.
Study: NCT05795192
Drug: SB17170
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taking SB17170 orally once a day
Study: NCT05795192
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taking Placebo orally once a day
Study: NCT05011513
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (tablet)
Study: NCT05011513
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (capsule)
Study: NCT04278989
Drug: Anti-tumor B
Normalized name: human breast tumor cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,200 mg, three times a day for seven to 28 days (dependent on scheduled surgery).
Study: NCT04648046
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Non-ablative conditioning with cyclophosphamide.
Study: NCT05099835
Drug: triamcinolonacetonide
Approvals — FDA: no, EMA: no, PMDA: no
Description: triamcinolonacetonide stellate ganglion injection
Study: NCT04676399
Drug: Hydrochlorothiazide 12.5mg
Normalized name: HYDROCHLOROTHIAZIDE 12.5MG CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 pills/day (1 pill every morning and 1 pill every evening) for 14 days.
Study: NCT04676399
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 pills/day (1 pill every morning and 1 pill every evening) for 14 days
Study: NCT05494437
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator
Study: NCT06583993
Drug: HNF4α srRNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: HNF4α srRNA will be administered intravenously for the treatment of ICC. The dosing regimen is planned for a second dose 14 ± 3 days post-initial treatment, followed by subsequent treatments every 28 ± 7 days, with adjustments made based on patient tolerance and therapeutic response.
Study: NCT06216210
Drug: opioid-FREE anesthesia.
Approvals — FDA: no, EMA: no, PMDA: no
Description: They received opioid-free anesthesia. These patients were provided a multimodal combination infusion. The administration of this infusion commenced at a dosage of 0.2 micrograms per kilogram per hour of dexmedetomidine. The Modified Mulimix cocktail, consisting of dexmedetomidine at a concentration of 10 ug/ml, Ketamine at a concentration of 2.5 mg/ml, and Lignocaine at a concentration of 20 mg/ml, was administered to a patient weighing 100 kg and if the weight is 110 Kg the rate will be increased by 10 percent, etc.,
Study: NCT06216210
Drug: opioid-CONTAINING anesthesia.
Approvals — FDA: no, EMA: no, PMDA: no
Description: The process of inducing anesthesia included the injection of fentanyl at a dosage of 2 micrograms per kilogram during the induction phase. Additionally, morphine was administered at a dose of 0.03 milligrams per kilogram at the time of port insertion.
Study: NCT05041270
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery will be started under spinal anesthesia. When sensory block regress to T12 dermatome Epidural bolus dose will be given epidural bolus dose of 12ml (10ml 0.25% bupivacaine + 2ml normal saline) The onset of sensory blockade injected epiduraly with maximal cephalic spread will be assessed by bilateral pinprick method along the midclavicular line, every 5 min for 30 min and then every 30 min.~top up dose of 8ml will be given postoperative (6ml 0.25% bupivacaine + 2ml normal saline).
Study: NCT04713514
Drug: OSE2101
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous injection on day 1, every 3 weeks for 7 doses then every 6 weeks up to week 48 and then every 12 weeks until intolerance, disease progression, or up to 2 years.
Study: NCT06414902
Drug: ArabinoFuranosylGuanine [18F]F-AraG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given by IV
Study: NCT05478863
Drug: Oral Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be orally self-administered by study participants.
Study: NCT05478863
Drug: Oral THC
Approvals — FDA: no, EMA: no, PMDA: no
Description: THC will be orally self-administered by study participants.
Study: NCT05478863
Drug: Oral CBD
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBD will be orally self-administered by study participants.
Study: NCT05478863
Drug: Oral Caffeine
Normalized name: caffeine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine will be orally self-administered by study participants.
Study: NCT05496569
Drug: TQB3616 capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQB3616 capsule is a cyclin-dependent kinase 4/6 kinase inhibitor
Study: NCT05496569
Drug: TQB3616 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04610398
Drug: NaCl 0.9%
Normalized name: DEXTROSE 5%/NACL 0.9% INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: s. arm/group description
Study: NCT04288193
Drug: Recommendation to Deprescribe
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recommendation to Deprescribe
Study: NCT04800237
Drug: VQW-765
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral capsule
Study: NCT04800237
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral capsule
Study: NCT05218642
Drug: KX- 826 dosed at 2.5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5mg of the investigational drug to be applied topically to scalp twice daily for 24 weeks
Study: NCT05218642
Drug: Matching placebo to KX-826
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo applied topically to scalp twice daily or once daily for 24 weeks
Study: NCT06522204
Drug: %5 Dextrose
Approvals — FDA: no, EMA: no, PMDA: no
Description: All the patients will receive oral 3mL/kg 5%Dextrose
Study: NCT05997927
Drug: VC005 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: VC005 groups repeat administration for 12 weeks
Study: NCT05997927
Drug: VC005 Tablets Placebo
Normalized name: PLACEBO TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: VC005 placebo groups repeat administration for 12 weeks
Study: NCT06583889
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The patients randomized to standard medical care will receive (or continue) either any type of body-weight adjusted low molecular weight heparin in therapeutic dose, or intravenous adjusted dose unfractionated heparin (aPTT value kept within 1 time the normal value), according to the existing international guidelines.
Study: NCT06549426
Drug: anti-seizure medication + sedative agent(s)
Normalized name: pramoxine hydrochloride Medicated Pad [Scalpicin Anti-Itch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stepwise approach:~1. a single dose of a parenteral benzodiazepine (lorazepam, midazolam, or diazepam) and a first parenteral anti-seizure medication (levetiracetam, valproate, or lacosamide)~2. a second parenteral anti-seizure medication plus a first continuous parenteral sedative agent (midazolam or propofol)~3. a second continuous parenteral sedative agent (midazolam, propofol, or ketamine)
Study: NCT06607484
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion
Study: NCT06622148
Drug: Iron Sucrose injection (Test product, manufactured by Sichuan Huiyu Pharmaceutical Co., Ltd) and Iron Sucrose injection (Reference product, Venofer)
Normalized name: iron sucrose Injection
DrugBank: Iron sucrose (DB09146)
Approvals — FDA: no, EMA: no, PMDA: no
Description: For the Group I, participants will receive a single intravenous injection of the Test Product (Iron sucrose injection, 100 mg iron/5 mL, manufactured by Sichuan Huiyu Pharmaceutical Co., Ltd). After a washout period, subjects will receive a single intravenous injection of the Reference Product (Iron sucrose injection, Venofer®, 100 mg iron/5 mL, held by AMERICAN REGENT, INC.) .
Study: NCT06622148
Drug: Iron Sucrose injection (Reference product, Venofer) and Iron Sucrose injection (Test product, manufactured by Sichuan Huiyu Pharmaceutical Co., Ltd)
Normalized name: iron sucrose Injection
DrugBank: Iron sucrose (DB09146)
Approvals — FDA: no, EMA: no, PMDA: no
Description: For the Group II, participants will receive a single intravenous injection of the Reference Product (Iron sucrose injection, Venofer®, 100 mg iron/5 mL, held by AMERICAN REGENT, INC.) . After a washout period, subjects will receive a single intravenous injection of the Test Product (Iron sucrose injection, 100 mg iron/5 mL, manufactured by Sichuan Huiyu Pharmaceutical Co., Ltd).
Study: NCT05416749
Drug: 8MW2311
Approvals — FDA: no, EMA: no, PMDA: no
Description: All subjects will receive a single intravenous (IV) infusion of 8MW2311 every 21 days (q21d), other dosing frequencies may be used.
Study: NCT06696703
Drug: Human urinary kininogenase(HUK)
Normalized name: kininogenase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental group (HUK plus routine clinical treatment): administered within 48 hours of AIS onset, 0.15PNA unit was dissolved in 100ml sodium chloride injection by intravenous infusion for not less than 50 minutes, once a day.
Study: NCT05541497
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Days 1-3: 0.5mg pill once per day, Days 4-7: 0.5mg pill twice per day, Weeks 2-8: 1mg pill twice per day
Study: NCT05199194
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of placebo, matching the volume of tenecteplase 0.25mg/kg
Study: NCT04744051
Drug: Placebo Infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each participant in this arm will receive a single dose of placebo. Upon completion of the study each placebo participant will with be given the option to be treated with their cultured adipose derived stem cells derived from their own adipose (fat) tissue via infusion therapy delivery over the course of one hour. Dosage for the crossover will be determined by the PI following review of data collected from the other arms of the study.
Study: NCT04814511
Drug: InfectoScab 5 % Creme
Approvals — FDA: no, EMA: no, PMDA: no
Description: InfectoScab 5 % Creme is the already approved standard therapeutic agent, containing the active ingredient permethrin in 5 % concentration. In this study, it is used for topical treatment in the first treatment cycle (standard therapy) as well as in the second treatment cycle (escalation therapy).
Study: NCT06055777
Drug: SZEY-2108 for injetion
Normalized name: gentamicin
DrugBank: Gentamicin (DB00798)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Part1（Single-dose intravenous infusion dose-escalation trial）:100mg，200mg，500mg, 1000mg, 2000mg，4000mg and the dose of last cohort to be determined. Single intravenous doses on D1；Part 2（Multi-dose intravenous infusion dose-escalation trial）：1000mg at Q8h，2000mg at Q8h, and one dose level of 1000mg, 1500mg or 2000mg at Q6h. Multiple intravenous doses of SZEY-2108 at Q8h or Q6h on D1\~D7 and on the morning of D8.
Study: NCT06055777
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part1（Single-dose intravenous infusion dose-escalation trial）:250mL/500mL，Single intravenous doses on D1；Part 2（Multi-dose intravenous infusion dose-escalation trial）：250mL,Multiple intravenous doses of placebo at Q8h or Q6h on D1\~D7 and on the morning of D8.
Study: NCT06309043
Drug: recombinant anti-EGFR human/murine chimeric monoclonal antibody injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: a single dose，250 mg/m2
Study: NCT05311475
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo nasal spray
Study: NCT05245656
Drug: RB/RBAC alternating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients assigned to the RB alternating with RBAC arm will receive six cycles of alternating RB (odd cycles) or RBAC (even cycles)~RB (1st, 3rd, and 5th cycles)~* Rituximab 375mg/m2, IV, D1~* Bendamustine 90mg/m2, IV, D1-2~RBAC (2nd, 4th, and 6th cycles)~* Rituximab 375mg/m2, IV, D1~* Bendamustine 70mg/m2, IV, D2-3~* Cytarabine 500mg/m2, IV, D2-4
Study: NCT04756960
Drug: CHF6001
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 inhalations of CHF6001 800 µg/20 mg NEXThaler® dry-powder inhaler (DPI), (total dose of 3200µg) co-administered with an intravenous microdose (18.5µg (18.5 kBq)) of \[14\^C\]-labelled CHF6001
Study: NCT05494060
Drug: XELOX
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capecitabine:1000 mg/m2 bid d1-14 q3w, Oxaliplatin:130 mg/m2 d1 q3w
Study: NCT05507203
Drug: ABX464
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered once daily in the morning with food
Study: NCT05507203
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered once daily in the morning with food
Study: NCT06726876
Drug: Normal saline rinses.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage: Patients will use 20 ml of normal saline.~Administration: Oral rinse, performed 3 times per day.~Instructions: Patients are instructed to rinse their mouths with the saline solution for a specified duration and avoid swallowing it.~Unique Elements:~Control Comparison: Provides a placebo comparison to evaluate the efficacy of the Manuka honey intervention.~Additional Procedures: Scaling and root debridement, along with the local application of 0.5 ml non-diluted Thyme honey on sites with Probing Pocket Depth (PPD) ≥ 5 mm.
Study: NCT06087211
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: will receive placebo capsule and an IV infusion of 200ml NS 1 hour before surgery
Study: NCT05978661
Drug: FKC288
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of FKC288 Four dose groups of 0.1×10\^6 CAR-T/kg, 0.3×10\^6 CAR-T/kg, 1.0×10\^6 CAR-T/kg, and 3.0×10\^6 CAR-T/kg FKC288 are designed in this study. 3 to 6 subjects are expected to be enrolled in each dose group according to observed DLT.
Study: NCT05238883
Drug: HFB200301
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be administered HFB200301 as described in the experimental arm.
Study: NCT04730947
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taken orally once a day, the placebo looks identical to the study drug but it contains no active ingredient
Study: NCT06300398
Drug: IAMA-6
Approvals — FDA: no, EMA: no, PMDA: no
Description: IAMA-6 liquid suspension
Study: NCT06300398
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-to-match IAMA-6 liquid suspension
Study: NCT06454292
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After subjects were enrolled, the original sedative and analgesic drugs were discontinued, and remifentanil was continuously pumped at a starting dose of 1.5ug/kg/h. The time of remifentanil initiation was recorded as T0. Subjects were assessed for sedation using the RASS score and analgesia using the CPOT score. We waited for the original sedative-analgesic drugs to elute until CPOT ≥ 3 and RASS \> 0. The infusion rate of remifentanil was adjusted according to the CPOT score (1.5ug/kg/h is recommended, the range of adjustment is 1.5\~12μg/kg/h, and the maximum infusion rate is not more than 12μg/kg/h) until the subject's analgesic score of CPOT\<3, and the interval between the two experimental rate adjustments of the drug should be ≧5min, and the CPOT score should be performed before each adjustment of the drug. The CPOT score should be performed before each drug adjustment.
Study: NCT06500286
Drug: Marciane
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A caudal block 0.25% bupivacaine was administered at a dose of 0.2 ml/k
Study: NCT06165926
Drug: 15% hypertonic dextrose
Approvals — FDA: no, EMA: no, PMDA: no
Description: The solution is prepared with 3 ml of 50% Dextrose, 1 ml of 2% xylocaine, and 6 ml of normal saline.~The ultrasound-guided injection of 15% hypertonic dextrose is performed at the first week. Subsequent ultrasound-guided shoulder joint injection treatment with hypertonic dextrose is performed at the fourth weeks. A total of 2 sessions of hypertonic dextrose injections are performed.
Study: NCT06165926
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: The solution is prepared with 1 ml of 2% xylocaine + 9 ml of normal saline. The ultrasound-guided injection of Normal saline(0.9%) is performed at the first week. Subsequent ultrasound-guided shoulder joint injection treatment with Normal saline is performed at the fourth weeks. A total of 2 sessions of Normal saline injections are performed.
Study: NCT06306846
Drug: Immunochemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD-1 monoclonal antibody and TP chemotheapy
Study: NCT04294836
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLACEBO Capsules 500mg
Study: NCT04855266
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (NaCl 0.9%) 5 mL/kg (maximum volume 210 mL)
Study: NCT04984577
Drug: Placebo injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injection, one dose every 12 hours, continue for 14 days
Study: NCT05356403
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet taken orally 1 time/day
Study: NCT06445816
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Parents whose consent was obtained will be asked to fill out the Mother and Child Information Collection Form and Psychological Resilience Scale, respectively.~* Immediately after receiving chemotherapy, the pain levels of the children will be measured with the Facial Expressions Pain Scale - Faces Pain Scale-Revised (FPS-R).~* The psychological resilience scale will be applied to mothers.
Study: NCT04642261
Drug: Placebo pills
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical in appearance to empagliflozin 10mg daily
Study: NCT06307093
Drug: Keytruda®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/4 mL (25 mg/mL) concentrate for solution for infusions in a single-dose vial~The required volume (8 ml) of the Drug concentrate solution should be withdrawn from the vials and transferred into an intravenous bag containing 0.9% Sodium Chloride Injection or 5% Dextrose Injection. (The final concentration of the diluted solution should be between 1 mg/mL to 10 mg/mL.)
Study: NCT05718219
Drug: SIM0348
Approvals — FDA: no, EMA: no, PMDA: no
Description: Several dose levels will be evaluated for SIM0348 administered as a single agent . SIM0348 will be given via IV infusion on Day 1,Day 8,Day 15,Day 22 of each cycle (28-day or depending on study cohort and phase) until disease progression or loss of clinical benefit.
Study: NCT05290740
Drug: Norepinephrine 5 mcg
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: norepinephrine bolus of 5 mcg for treatment of sever postspinal hypotension
Study: NCT05290740
Drug: Norepinephrine 10 mcg
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: norepinephrine bolus of 10 mcg for treatment of sever postspinal hypotension
Study: NCT05126836
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05390645
Drug: MFA-370
Approvals — FDA: no, EMA: no, PMDA: no
Description: MFA-370 is a treatment with a combination of two approved pharmaceuticals
Study: NCT06489249
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo tablet
Study: NCT06489249
Drug: Salsalate 750 MG Oral Tablet [DISALCID]
Normalized name: salsalate 750 MG Oral Tablet [Disalcid]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral salsalate tablet
Study: NCT05939947
Drug: ALE.F02
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous (IV) infusion administered once every second week to a total of 3 doses.
Study: NCT05939947
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous (IV) infusion administered once every second week to a total of 3 doses.
Study: NCT05278988
Drug: PRS Regimen V
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRS Regimen V(bedaquiline, delamanid, clofazimine, pyrazinamide)
Study: NCT05278988
Drug: MDR-TB Treatment Regimen(WHO)
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment according to WHO MDR-TB treatment guidelines (2019)
Study: NCT04942054
Drug: Part 1
Normalized name: INSULIN,ASPART 100 UNIT/ML 3ML CART
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose escalation cohort
Study: NCT06519370
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000 to 1250 mg/m\^2 will be administered in a 21-day cycle, with capecitabine administered orally twice daily for 2 weeks followed by 1-week rest
Study: NCT05216341
Drug: OLP-1002
Normalized name: benzocaine
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stage 1: A total of 5 participants will be enrolled in each arm in Stage 1.~Each participant will receive one single dose of OLP-1002 by subcutaneous injection.~Stage 2: Up to 90 participants will be randomised on Day 1 to one of 3 treatment arms, in the ratio of 1:1:1 to receive one single dose of OLP-1002 (1 µg or 2 µg) or placebo.~Each participant will receive one single dose of OLP-1002 or placebo by subcutaneous injection.
Study: NCT00657579
Drug: DE-104 ophthalmic solution, low concentration
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00657579
Drug: DE-104 ophthalmic solution, medium concentration
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00657579
Drug: DE-104 ophthalmic solution, high concentration
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05473520
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A dose of 100 mg twice daily of doxycycline based on the recommended dose for adults which is commonly used for bacterial infections such as rickettsial infection, lyme disease and pelvic inflammatory disease.
Study: NCT05473520
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + standard anti-tuberculous treatment
Study: NCT06610799
Drug: IBI363
Approvals — FDA: no, EMA: no, PMDA: no
Description: IBI363 Q3W Oxaliplatin 130 mg/m2，IV，Q3W, Capecitabine ,1000mg/ m2，PO，Bid，d1-14，Q3W